ATE218552T1 - 1,2,4-TRIAZIN DERIVAT, DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ALS REFERENZMARKER UM DIE REINHEIT UND STABILITÄT VON ßLAMOTRIGINß ZU BESTIMMEN - Google Patents

1,2,4-TRIAZIN DERIVAT, DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ALS REFERENZMARKER UM DIE REINHEIT UND STABILITÄT VON ßLAMOTRIGINß ZU BESTIMMEN

Info

Publication number
ATE218552T1
ATE218552T1 AT99200695T AT99200695T ATE218552T1 AT E218552 T1 ATE218552 T1 AT E218552T1 AT 99200695 T AT99200695 T AT 99200695T AT 99200695 T AT99200695 T AT 99200695T AT E218552 T1 ATE218552 T1 AT E218552T1
Authority
AT
Austria
Prior art keywords
ßlamotrigine
purity
stability
production
reference marker
Prior art date
Application number
AT99200695T
Other languages
English (en)
Inventor
Lorraine Mary Edmeades
Nigel Arthur Griffith-Skinner
Derek Anthony Hill
Graham Thornton Hill
Terrence William Packham
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE218552(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE218552T1 publication Critical patent/ATE218552T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT99200695T 1998-06-10 1999-03-10 1,2,4-TRIAZIN DERIVAT, DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ALS REFERENZMARKER UM DIE REINHEIT UND STABILITÄT VON ßLAMOTRIGINß ZU BESTIMMEN ATE218552T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (1)

Publication Number Publication Date
ATE218552T1 true ATE218552T1 (de) 2002-06-15

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99200695T ATE218552T1 (de) 1998-06-10 1999-03-10 1,2,4-TRIAZIN DERIVAT, DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ALS REFERENZMARKER UM DIE REINHEIT UND STABILITÄT VON ßLAMOTRIGINß ZU BESTIMMEN

Country Status (31)

Country Link
US (1) US6333198B1 (de)
EP (2) EP1170588A1 (de)
JP (1) JP2989189B1 (de)
KR (1) KR100322354B1 (de)
CN (2) CN1238454A (de)
AP (3) AP9901481A0 (de)
AR (1) AR014074A1 (de)
AT (1) ATE218552T1 (de)
AU (1) AU2031999A (de)
BR (1) BR9900984A (de)
CA (1) CA2265194C (de)
DE (1) DE69901656T2 (de)
DK (1) DK0963980T3 (de)
EA (1) EA000666B1 (de)
ES (1) ES2178342T3 (de)
GB (1) GB9812413D0 (de)
HR (1) HRP990074A2 (de)
HU (1) HUP9900592A3 (de)
ID (1) ID22957A (de)
MA (1) MA24777A1 (de)
NO (2) NO991151L (de)
NZ (1) NZ334590A (de)
PE (1) PE20000332A1 (de)
PL (1) PL331870A1 (de)
PT (1) PT963980E (de)
SG (1) SG85628A1 (de)
SI (1) SI0963980T1 (de)
TR (1) TR199900520A3 (de)
UY (1) UY25946A1 (de)
YU (1) YU12399A (de)
ZA (1) ZA991951B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
AU763244B2 (en) * 2000-01-03 2003-07-17 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
WO2002053541A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
EP1309558A1 (de) 2000-12-29 2003-05-14 Synthon Licensing, Ltd. Aspartat-derivat von amlodipine als kalzium-kanal antagonist
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
IL156692A0 (en) 2000-12-29 2004-01-04 Pfizer Ltd Process for making amlodipine maleate
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
BR0116552A (pt) 2000-12-29 2004-02-03 Pfizer Ltd Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão
EP1346214A2 (de) * 2000-12-29 2003-09-24 Pfizer Limited Referenzstandards und verfahren zur bestimmung der reinheit oder stabilität von amlodipin-maleat
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
DE10134980C2 (de) * 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
IL164155A0 (en) * 2002-03-20 2005-12-18 Teva Pharma Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) * 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
US7777034B2 (en) * 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP1689723B1 (de) * 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Referenzstandard zur charakterisierung von rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
EP1709002A2 (de) * 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast-natrium-polymorphe
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
KR100815670B1 (ko) * 2004-04-21 2008-03-20 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트 나트륨을 제조하는 방법
WO2005105768A2 (en) 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005660A (es) * 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Impureza de micofenolato mofetil.
CA2561387A1 (en) * 2004-06-28 2006-01-12 Teva Pharmaceutical Fine Chemicals S.R.L. An isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
EP1673351A1 (de) * 2004-07-13 2006-06-28 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von rosuvastatin mit einem durch tempo vermittelten oxidationsschritt
EP1908756A1 (de) * 2004-07-20 2008-04-09 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Herstellungsverfahren für kristallines Mycophenolat-Natrium
WO2006020348A2 (en) * 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
EP1692134A2 (de) * 2004-09-04 2006-08-23 Teva Pharmaceutical Industries, Inc. Valacyclovir-verunreinigung, herstellungsverfahren dafür und verwendung als referenzstandard
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
ES2263407T1 (es) * 2004-09-28 2006-12-16 Teva Pharmaceutical Industries Ltd Procedimiento para la preparacion de formas de atorvastatina calcica sustancialmente libres de impurezas.
JP2007514777A (ja) * 2004-10-19 2007-06-07 テバ ファーマシューティカル インダストリーズ リミティド テガセロッドマレエートの精製
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
US20060194869A1 (en) * 2004-12-23 2006-08-31 Santiago Ini Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
HRP20090676T1 (hr) * 2005-01-11 2010-01-31 Teva Pharmaceutical Fine Chemicals S.R.L. Postupak dobivanja 1-amino-3,5-dimetiladamantan-hidroklorida
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
CA2591439C (en) * 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
JP2008530028A (ja) * 2005-02-24 2008-08-07 テバ ファーマシューティカル インダストリーズ リミティド リネゾリッド中間体の調製方法
WO2006099433A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Pure duloxetine hydrochloride
EP1751085A1 (de) * 2005-04-05 2007-02-14 Teva Pharmaceutical Fine Chemicals S.R.L. Stabiles atomoxetinhydrochlorid, herstellungsverfahren und analytische steuerung seiner stabilität
US7417165B2 (en) * 2005-04-06 2008-08-26 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
US20070066846A1 (en) * 2005-04-11 2007-03-22 Asher Maymon Process for making (S)-Pregabalin
US7687622B2 (en) * 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP1879851B1 (de) * 2005-05-10 2010-11-03 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung von pregabalin und salzen daraus
KR20090019016A (ko) * 2005-05-10 2009-02-24 테바 파마슈티컬 인더스트리즈 리미티드 3-카르바모일메틸-5-메틸 헥산산의 광학 분할
KR20070067077A (ko) * 2005-05-10 2007-06-27 테바 파마슈티컬 인더스트리즈 리미티드 이소부틸글루타르산을 함유하지 않는 프레가발린 및 이의제조 방법
WO2006121557A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
CA2606099A1 (en) 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Processes for preparing cinacalcet hydrochloride crystal form i
WO2007002720A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. An impurity of anastrozole intermediate, and uses thereof
CN101233100A (zh) * 2005-06-27 2008-07-30 西科尔公司 阿那曲唑中间体的杂质及其应用
US7812168B2 (en) * 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
MX2007004427A (es) * 2005-08-16 2007-06-14 Teva Pharma Intermedio de rosuvastatina cristalina.
CA2619472A1 (en) * 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
EP1863782A1 (de) * 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamin)-3-(2-naphthol) thiophen, eine verunreinigung von duloxetin hydrochlorid
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
EP1891034A2 (de) * 2005-12-27 2008-02-27 Teva Pharmaceutical Fine Chemicals S.R.L. Verfahren zur herstellung von darifenacin-hydrobromid
BRPI0702852A2 (pt) * 2006-03-27 2012-08-07 Teva Pharmaceutical Ind Ltda processos para preparaÇço de Ácido hidroclorÍdrico de memantine substancialmente livre de impurezas, para determinar o grau de pureza do mesmo e para fabricaÇço de produto famacÊutico derivado; seus compostos e componentes
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
WO2007139933A2 (en) * 2006-05-24 2007-12-06 Teva Pharmaceutical Industries Ltd. Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
WO2007143152A2 (en) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. Preparation of (s)-pregabalin-nitrile
EP1913147A2 (de) * 2006-05-31 2008-04-23 Teva Pharmaceutical Industries Ltd Enzymatische auflösung für die herstellung von pregabalin-zwischenprodukten
WO2008002665A1 (en) * 2006-06-29 2008-01-03 Teva Pharmaceutical Industries Ltd. Regulation of acid metabolite production
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
WO2008019798A1 (en) * 2006-08-14 2008-02-21 Lonza Ag A process for the preparation of lamotrigine
EP2139845A1 (de) * 2007-02-26 2010-01-06 Teva Pharmaceutical Industries Ltd. Zwischenprodukte und verfahren zur synthese von ramelteon
CA2681313C (en) * 2007-03-22 2012-09-11 Teva Pharmaceutical Industries Ltd. Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
EP2024506A1 (de) * 2007-04-11 2009-02-18 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Verfahren zur reduzierung des verunreinigungslevels bei der myophenolsäure-fermentierung
US8084630B2 (en) * 2007-05-31 2011-12-27 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US20090137842A1 (en) * 2007-10-03 2009-05-28 Vollerner Yuri Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
WO2009053854A2 (en) * 2007-10-23 2009-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
US20090281176A1 (en) * 2007-11-01 2009-11-12 Vinod Kumar Kansal Process for the synthesis of ramelteon and its intermediates
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
WO2009151494A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
US8569371B2 (en) * 2010-03-29 2013-10-29 Pliva Hrvatska D.O.O. Crystal forms of O-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
CN110467560B (zh) 2018-05-09 2025-11-25 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49823B1 (en) 1979-06-01 1985-12-25 Wellcome Found 1,2,4-triazine derivatives,process for preparing such compounds and pharmaceutical compositions containing them
EP0021120B1 (de) 1979-06-01 1983-04-06 The Wellcome Foundation Limited 3,5-Diamino-1,2,4-triazin-Derivate, Verfahren zur Herstellung dieser Verbindungen und pharmazeutische Zusammensetzungen sie enthaltend
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
ES2177672T3 (es) * 1994-12-30 2002-12-16 Wellcome Found Procedimiento para preparacion de lamotrigina.
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Also Published As

Publication number Publication date
NO991151L (no) 1999-12-13
NZ334590A (en) 2000-07-28
EP0963980B1 (de) 2002-06-05
UY25946A1 (es) 2000-12-29
JP2000009714A (ja) 2000-01-14
CN1238454A (zh) 1999-12-15
DE69901656D1 (de) 2002-07-11
AP2001002286A0 (en) 2001-12-31
ID22957A (id) 1999-12-23
PE20000332A1 (es) 2000-04-10
ZA991951B (en) 1999-08-16
JP2989189B1 (ja) 1999-12-13
CN1306210A (zh) 2001-08-01
DK0963980T3 (da) 2002-09-16
DE69901656T2 (de) 2003-01-30
NO20032753L (no) 1999-12-13
BR9900984A (pt) 2000-05-02
SI0963980T1 (en) 2002-12-31
HU9900592D0 (en) 1999-04-28
AU2031999A (en) 2000-01-06
EA000666B1 (ru) 2000-02-28
MA24777A1 (fr) 1999-10-01
NO20032753D0 (no) 2003-06-17
GB9812413D0 (en) 1998-08-05
KR100322354B1 (ko) 2002-02-07
CA2265194C (en) 2000-10-10
HUP9900592A2 (hu) 2000-04-28
AP9901481A0 (en) 1999-03-31
PT963980E (pt) 2002-10-31
HUP9900592A3 (en) 2002-04-29
EP1170588A1 (de) 2002-01-09
AP0102286A0 (en) 2000-09-10
TR199900520A2 (en) 2000-01-21
SG85628A1 (en) 2002-01-15
YU12399A (sh) 2002-08-12
KR20000005611A (ko) 2000-01-25
AR014074A1 (es) 2001-01-31
NO991151D0 (no) 1999-03-10
EP0963980A3 (de) 2000-05-31
ES2178342T3 (es) 2002-12-16
US6333198B1 (en) 2001-12-25
PL331870A1 (en) 1999-12-20
HRP990074A2 (en) 2000-10-31
EP0963980A2 (de) 1999-12-15
TR199900520A3 (tr) 2000-01-21
EA199900159A1 (ru) 1999-12-29

Similar Documents

Publication Publication Date Title
ATE218552T1 (de) 1,2,4-TRIAZIN DERIVAT, DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ALS REFERENZMARKER UM DIE REINHEIT UND STABILITÄT VON ßLAMOTRIGINß ZU BESTIMMEN
DE59510597D1 (de) 3-aryl-tetronsäure-derivate, deren herstellung und deren verwendung als schädlingsbekämpfungsmittel
ATE259806T1 (de) 8-azabicyclo 3.2.1)octan-, 8-azabicyclo 3.2.1)oct-6-en-, 9-azabicyclo 3.3.1)nonan-, 9-aza-3- oxabicyclo 3.3.1)nonan- und 9-aza-3-thiabicyclo 3.3.1)nonan-derivate, ihre herstellung und ihre verwendung als insektizide
DE59907464D1 (de) 1,3-oxazolin- und 1,3-thiazolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel
FI960227A7 (fi) 2,8-disubstituoidut kinatsolinonit
ATE299148T1 (de) Substituierte isochinolin-3-carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
DE69916828D1 (de) Pyrazoline, ihre herstellung und verwendung als medikamente
PT925298E (pt) Derivados 6,6-hetero-biciclicos substituidos
ATE239693T1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
DE69627411D1 (de) Triazinderivate, ihre Herstellung und Verwendung
ATE169017T1 (de) Substituierte pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ATE248169T1 (de) 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate
DE69904249D1 (de) 2,2-Dimethylcyclopropansäureester und ihre Verwendung als Pestizide
ATE214371T1 (de) 3-hydroxy-pyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
DE10084441T1 (de) Koalinton-Pigmente, ihre Herstellung und Verwendung
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
DE69821623D1 (de) Derivate von acyl-piperazinil-pyrimidinen, ihre herstellung und verwendung als medikament
ATE73758T1 (de) 2,2-difluorcyclopropylethanderivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel.
DE69511579D1 (de) Biozide alkohole, ihre herstellung und ihre verwendung
DE60044925D1 (de) Die Verwendung einer Riechstoffzusammensetzung enthaltend Anisaldehyd
ATE268760T1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
DE59811477D1 (de) Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69723463D1 (de) Cyclische organoselenderivate, ihre herstellung und verwendung
DE69908371D1 (de) Thioethergruppen enthaltende distamycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
FI941149L (fi) 2,4-diamino-3-hydroksikarboksyylihapon johdannaisia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee